drugset

drugset / Trial / NCT07021976

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07021976 ↗

Phase 3 Recruiting 216 enrolled Shandong Suncadia Medicine Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.

Timeline

Start: 2025-08-11
Primary completion: 2026-09
Completion: 2026-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-1893	Unknown	—	—

Indications